Entheon Biomedical Corp. ENBIX
CNSX
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 81.01% | -31.72% | -23.35% | -25.87% | -52.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.01% | -31.72% | -23.35% | -25.87% | -52.20% |
| Operating Income | -81.01% | 31.72% | 23.35% | 25.87% | 52.20% |
| Income Before Tax | 492.81% | 28.61% | 23.48% | 27.33% | 31.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 492.81% | 28.61% | 23.48% | 27.33% | 31.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 492.81% | 28.61% | 23.48% | 27.33% | 31.84% |
| EBIT | -81.01% | 31.72% | 23.35% | 25.87% | 52.20% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 494.12% | 58.82% | 50.72% | 52.83% | 64.21% |
| Normalized Basic EPS | -47.62% | 58.49% | 51.16% | 54.55% | 64.41% |
| EPS Diluted | 494.12% | 58.82% | 50.72% | 52.83% | 64.21% |
| Normalized Diluted EPS | -47.62% | 58.49% | 51.16% | 54.55% | 64.41% |
| Average Basic Shares Outstanding | 0.00% | 71.37% | 56.57% | 56.44% | 89.33% |
| Average Diluted Shares Outstanding | 0.00% | 71.37% | 56.57% | 56.44% | 89.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |